Lumosa Therapeutics Co., Ltd.

Taipei Exchange 6535.TWO

Lumosa Therapeutics Co., Ltd. Gross Profit Margin for the year ending December 31, 2023: 72.88%

Lumosa Therapeutics Co., Ltd. Gross Profit Margin is 72.88% for the year ending December 31, 2023, a 33.35% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.
  • Lumosa Therapeutics Co., Ltd. Gross Profit Margin for the year ending December 31, 2022 was 54.65%, a -4.04% change year over year.
  • Lumosa Therapeutics Co., Ltd. Gross Profit Margin for the year ending December 31, 2021 was 56.96%, a -6.27% change year over year.
  • Lumosa Therapeutics Co., Ltd. Gross Profit Margin for the year ending December 31, 2020 was 60.77%, a -0.26% change year over year.
  • Lumosa Therapeutics Co., Ltd. Gross Profit Margin for the year ending December 31, 2019 was 60.93%.
Key data
Date Gross Profit Margin Operating Income Margin EBT Margin Net Income Margin
Market news
Taipei Exchange: 6535.TWO

Lumosa Therapeutics Co., Ltd.

CEO Li Fang Pan
IPO Date July 16, 2015
Location
Headquarters No. 3-2, Park Street
Employees 47
Sector Health Care
Industries
Pharmaceuticals Biotechnology Clinical Trials
Description

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan. The company offers LT - 1001, an analgesic injection that has completed Phase III clinical trials for severe pain relief after surgery. It is also developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase Ib clinical trial for uremic pruritus; and LT2003, which is in pre-clinical stage for the treatment of oncology. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is based in Taipei, Taiwan.

StockViz Staff

January 15, 2025

Any question? Send us an email